Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Home
Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Next Post
Previous Post
Response to Treatment With
nab
-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
March 26, 2023
/
Publications
Like
this post!
Share
the Post
About
the Author
John Copertino
Related
Posts
Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (
nab
-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009,
nab
-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial
Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of
nab
-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
and
TSC2
(PRECISION 1)
Inactivating
TSC1
and
TSC2
alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient population using the Foundation Medicine genomic database
Real-world (RW) characterization and frequency of
TSC1
and/or
TSC2
alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.